Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.…
Does Wider Losses Change The Bull Case For Trevi Therapeutics Stock (TRVI)?
Trevi Therapeutics (NASDAQ: TRVI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 13.35 USD on 20 November 2026, up 21.3% over 52 weeks. Its 52-week range is 9.820 USD to 20.15 USD: the price is 33.7% below the high and 35.9% above the low.
Its market capitalisation is 1.90B USD.
Trevi Therapeutics reports return on equity of -23.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 298.88M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 28.18 USD is 111.1% above the current price. The next earnings report is expected on 16 March 2027.